272
|
CovidReference.com
the end of the year. Sanofi and GSK seem to investigate if a lower dose of their vaccine could generate a strong booster response in people previously vaccinated with other vaccines. Trivia Sanofi and GSK initially aimed at a production of 1 billion doses in 2021 but an “unfortunate setback” – a laboratory error due to reagents of poor quality or purity? (Aeberhardt 2021) – led to an insufficient immune response in older adults in a previous Phase I/II trial (Sanofi 20201211). The setback delayed the development of the Sanofi/GSK vaccine by five to six months.
Outlook The immediate prospects of the COVID-19 pandemic are excellent, good or undetermined – depending on where you live.
Israel The immediate prospects seem to be excellent for Israel (Balicier 2021). Soon, 60% of the total population will be fully vaccinated (Figure 2, green dots) which corresponds to more than 85% of the adult population as a third of the population is less than 16 years old. At the end of April, four months after the beginning of the vaccination campaign, the vast majority of adults had been vaccinated (see Table 14). Table 14. Israel, percentage of adults having received the first vaccine dose (by age group, end of April 2021): +90 years
99.2%
80-89
95.8%
70-79
98.3%
60-69
89.9%
50-59
88.9%
40-49
84.3%
30-39
80.3%
20-29
76.2%
Despite an almost fully open economy since 7 March, the number of new daily cases has steadily declined ever since (Figure 2, red dashed line). From the peak in mid-January, the number of daily new cases has fallen by 98%, the
Kamps – Hoffmann
